You Position: Home > Paper
Anlotinib-induced posterior reversible encephalopathy syndrome: a case report and literature review
( views:22, downloads:21 )
- Author:
- No author available
- Journal Title:
- China Medicine
- Issue:
- 12
- DOI:
- 10.3760/j.issn.1673-4777.2022.12.025
- Key Word:
- 可逆性后部脑病综合征;安罗替尼;酪氨酸激酶抑制剂
Abstract： 可逆性后部脑病综合征(PRES)是一种亚急性神经系统综合征,主要表现为头痛、皮质盲及癫痫发作.但其病因复杂,发病机制不详,经常难以准确判断.目前已有文献报道多种靶向药物可以导致PRES,如贝伐珠单抗、索拉非尼.安罗替尼是我国自主研发的一种口服多靶点酪氨酸激酶抑制剂,临床研究已经证实,安罗替尼在肺癌、甲状腺髓样癌及肾细胞癌等多种恶性肿瘤的治疗中可改善患者生存预后.在对安罗替尼的不良反应监测中,安罗替尼相关的PRES少见报道.本文报道1例由安罗替尼诱发的PRES,并对相关文献进行复习,以提高临床医师对于该病的认识.
- [1]梁丹,农先胜,李彬,等.安罗替尼一线治疗不耐受或拒绝化疗的驱动基因阴性的晚期NSCLC患者：一项多中心、前瞻性研究[J].2022,35(7).
- [2]韩丽娟,李政,黄嵘,等.可逆性后部白质脑病综合征临床及影像学特点分析[J].2022,19(2).
- [3]崔广华,杨宇.安罗替尼在晚期恶性肿瘤治疗中的研究进展[J].2022,30(16).
- [4]蒙冲,董文,黄奕江,等.安罗替尼与安维汀分别联合化疗治疗非鳞状非小细胞肺癌的疗效及安全性[J].2020,(11).
- [5]刘玉霞,宋旭霞,李冬梅.可逆性后部白质脑病综合征21例临床分析[J].2017,(8).
- [6]王静怡,董量,付浩宇,等.安罗替尼二三线治疗的广泛期小细胞肺癌患者预后分析[J].2021,(1).
- [7]黄伟,解玉卓,赵涵,等.安罗替尼抗肿瘤疗效的研究进展[J].2019,(9).
- [8]方颖,刘晓巍.29例子痫患者的临床特征分析[J].2022,57(4).
- [9]杨丽菲,路鹏霏,刘俊远,等.安罗替尼单药与联合其他方案多线治疗老年消化道肿瘤患者的效果和安全性[J].2022,17(5).
- [10]Touyz, Rhian M.,Lang, Ninian N.,Herrmann, Joerg,etc.Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition[J].2017,70(2).
- [11]Haijun, Zhang.Apatinib for molecular targeted therapy in tumor.[J].2015,9.
- [12]Jayson, Gordon C.,Kerbel, Robert,Ellis, Lee M.,etc.Antiangiogenic therapy in oncology: current status and future directions[J].2016,388(10043).
- [13]Han, Baohui,Li, Kai,Wang, Qiming,etc.Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial[J].2018,4(11).
- [14]Fugate, Jennifer E.,Rabinstein, Alejandro A..Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions[J].2015,14(9).
- [15]Fischer, Marlene,Schmutzhard, Erich.Posterior reversible encephalopathy syndrome[J].2017,264(8).